CAS NO: | 1191386-55-6 |
包装 | 价格(元) |
10mg | 电议 |
50mg | 电议 |
100mg | 电议 |
200mg | 电议 |
500mg | 电议 |
生物活性 | Bivalirudin TFA is a synthetic 20 residue peptide which reversibly inhibitsthrombin. IC50 Value: Target:thrombinin vitro: Eptifibatide (8 mg/mL) added together with a low (70 ng/mL) concentration of bivalirudin (a directthrombininhibitor) effectively (approximately 90%) reduced platelet aggregation induced bythrombin(0.2 U/mL) [1]. Inthrombingeneration assay (TGA), bivalirudin had no effect on these parameters up to 10 μmol/l [2]. Bivalirudin-facilitated binding of MPO to BAEC resulted also in functional changes in terms of increased NO consumption as well as enhanced MPO-mediated redox modifications [3]. in vivo: The use of bivalirudinprevented further increase in antiheparin/PF4 antibodyIgGlevels in rats [4]. Threeanimalsin the 500-mg/kg/24 h group, and 7animalsin the 2000-mg/kg/24 h group in the toxicokinetic assessment phase of the study were found dead or euthanized in extremis (following blood sampling). Plasma concentrations of bivalirudin appeared to be linear and dose independent [5]. Clinical trial: Antithrombotic Effects of Ticagrelor Versus Clopidogrel . Phase 4 | ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 2294.34 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C98H138N24O33.C2HF3O2 | ||||||||||||||||
CAS 号 | 1191386-55-6 | ||||||||||||||||
Sequence | {d-Phe}-Pro-Arg-Pro-Gly-Gly-Gly-Gly-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu | ||||||||||||||||
Sequence Shortening | {d-Phe}-PRPGGGGNGDFEEIPEEYL | ||||||||||||||||
中文名称 | 三氟醋酸比伐卢定 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 | Sealed storage, away from moisture and light
*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light) | ||||||||||||||||
溶解性数据 | In Vitro: H2O : ≥ 50 mg/mL(21.79 mM) DMSO : ≥ 31 mg/mL(13.51 mM) *"≥" means soluble, but saturation unknown. 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|